In short
Clinical trials investigating Lithium are studying how it performs in people with mood and psychotic disorders. The trial data here focus on whether Lithium is part of an intensified treatment strategy after first-line treatment failure, with outcomes such as symptom improvement and safety-related study goals in specific patient groups.
Key points
- Clinical trials investigating Lithium in the provided data are part of a larger Phase 3 study of intensified treatment after first-line treatment failure. The trial includes people with schizophrenia spectrum disorders, major depressive disorder, and bipolar depression. Lithium is one of the medicines listed in the treatment plan for the study. The main goal is to compare symptom improvement with early intensified treatment versus treatment as usual. The main outcome is change in symptom severity, measured with standard rating scales that differ by diagnosis.
Trial overview
The trial data provided here describe one interventional study, meaning researchers assigned treatment plans and then measured the results. The study is titled as a randomized, controlled trial of early intensified pharmacological treatment compared with treatment as usual after first-line treatment failure. Lithium is one of the medicines listed in the treatment plans used in this study.
Who was studied
The study included people with schizophrenia, schizoaffective disorder, schizophreniform disorder, major depressive disorder, or bipolar disorder type I or II when they were currently in a depressive episode. The trial focused on people who had a first-time treatment failure on their first-line treatment, which means the first treatment did not work well enough.
The study was divided into different sample groups for different diagnoses, but the overall goal was the same across them. That goal was to see whether early intensified treatment could improve symptoms more than usual care.
What was tested
The main comparison was between an early intensified pharmacological treatment plan and treatment as usual. The trial title and summary show that the study looked at several medicines across different diagnosis groups, and Lithium was included among them.
For patients, this means the study was not testing Lithium alone in the source data provided here. Instead, Lithium was part of a broader treatment strategy being evaluated in people who did not respond well to their first treatment.
Outcomes and measurements
The primary outcome was change in symptom severity from the starting visit to the follow-up visit. The follow-up time was four weeks for major depressive disorder and six weeks for schizophrenia and bipolar depression.
Different rating scales were used based on the condition being studied. For schizophrenia spectrum disorders, the study used the Positive And Negative Syndrome Scale, which measures symptom severity in schizophrenia-related illness. For major depressive disorder and bipolar depression, the study used the Montgomery Asberg Depression Rating Scale, which measures depression symptoms.
Study status and size
The trial status is listed as Withdrawn, which means it did not continue as planned. The planned enrollment was 1254 participants, showing that this was intended to be a large Phase 3 study. The phase was Phase 3, a later stage of research that usually checks how well a treatment works in a larger group of people.